Finance

Lists
AUROPHARMA:NSE
Aurobindo Pharma Ltd
1 666,90 INR
-0,66%
(-11,00) 1D
16-окт., 15:30:00 GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for AUROPHARMA...
Open
1 677,90 INR
High
1 681,70 INR
Low
1 655,00 INR
Mkt. cap
959,10 млд
Avg. vol.
778,73 миң
Volume
796,73 миң
P/E ratio
26,04
52-wk high
1 740,00 INR
52-wk low
1 080,10 INR
EPS
64,00 INR
Shares outstanding
585,90 млн
No. of employees
29 миң
Open
1 677,90 INR
High
1 681,70 INR
Low
1 655,00 INR
Mkt. cap
959,10 млд
Avg. vol.
778,73 миң
Volume
796,73 миң
P/E ratio
26,04
52-wk high
1 740,00 INR
52-wk low
1 080,10 INR
EPS
64,00 INR
Shares outstanding
585,90 млн
No. of employees
29 миң
News stories
From web sources and news partners
Profile
Aurobindo Pharma Limited is an Indian multinational pharmaceutical manufacturing company based in HITEC City, Hyderabad, with U.S. headquarters in East Windsor, Mercer County, New Jersey. The company manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's area of activity includes six major therapeutic and product areas: antibiotics, anti-retrovirals, cardiovascular products, central nervous system products, gastroenterologicals, and anti-allergics. The company markets these products in over 125 countries. Its marketing partners include Pfizer and AstraZeneca. Wikipedia
About Aurobindo Pharma Ltd
CEO-
Employees29,2 миң
Founded1986
HeadquartersHyderabad, Эндра Прадеш, Индия
SectorPharmaceutical industry
Last report
2026-ж., 6-авг.
Fiscal period
Q1 2027
17,46 INR / 17,26 INR
+1,17%beat
Revenue / Est. (INR)
91,50 млд / 89,98 млд
+1,69%beat
Fiscal Q1 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Revenue
Net income
All values in INR
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
82,86 млд
86,46 млд
88,53 млд
91,50 млд
Cost of goods sold
33,39 млд
34,81 млд
39,28 млд
36,27 млд
Cost of revenue
33,39 млд
34,81 млд
39,28 млд
36,27 млд
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
12,77 млд
13,10 млд
14,31 млд
14,80 млд
Operating expense
36,98 млд
38,56 млд
35,29 млд
41,29 млд
Total operating expenses
70,37 млд
73,37 млд
74,57 млд
77,56 млд
Operating income
12,49 млд
13,09 млд
13,96 млд
13,94 млд
Other non operating income
1,16 млд
1,54 млд
-2,51 млд
2,12 млд
EBT including unusual items
12,76 млд
13,39 млд
12,91 млд
15,15 млд
EBT excluding unusual items
12,76 млд
14,04 млд
13,59 млд
15,55 млд
Income tax expense
4,28 млд
4,29 млд
3,70 млд
4,83 млд
Effective tax rate
33,53%
32,03%
28,65%
31,88%
Other operating expenses
19,91 млд
20,81 млд
16,37 млд
21,62 млд
Net income
8,48 млд
9,10 млд
9,21 млд
10,33 млд
Net profit margin
10,24%
10,53%
10,41%
11,28%
Earnings per share
14,61
16,43
15,86
17,46
Interest and investment income
-
-
3,31 млд
-
Interest expense
-952,40 млн
-927,70 млн
-665,50 млн
-1,02 млд
Net interest expenses
-952,40 млн
-927,70 млн
2,65 млд
-1,02 млд
Depreciation and amortization charges
4,29 млд
4,65 млд
4,61 млд
4,87 млд
EBITDA
16,66 млд
16,71 млд
18,03 млд
18,01 млд
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google колдонмолору